Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Non-infectious Uveitis

In brief

This extension study will assess the safety and efficacy of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression

Key facts

Study ID

NCT01090310

Run by

Novartis Pharmaceuticals

People needed

86

Starts

2010-08-01

Expected to finish

2011-07-01

Last updated by the study team

2016-01-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who have completed the entire treatment period of the 24 week core study

You may not qualify if…

• Inability or unwillingness to undergo repeated subcutaneous injections; inability to comply with study or follow-up procedures; any medical or psychiatric condition which, in the investigator's opinion wouldpreclude the participant from adhering to the protocol or completing the study per protocol.
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• Novartis Investigative Site — Portland, Oregon, United States
• Novartis Investigative Site — Arlington, Texas, United States
• Novartis Investigative Site — Houston, Texas, United States
• Novartis Investigative Site — São Paulo, São Paulo, Brazil
• Novartis Investigative Site — São Paulo, São Paulo, Brazil
• Novartis Investigative Site — Berlin, Germany
• Novartis Investigative Site — Kiel, Germany
• Novartis Investigative Site — Tübingen, Germany
• Novartis Investigative Site — New Delhi, India
• Novartis Investigative Site — Jerusalem, Israel
• Novartis Investigative Site — Petah Tikva, Israel
• Novartis Investigative Site — Ramat Gan, Israel
• Novartis Investigative Site — Tel Aviv, Israel
• Novartis Investigative Site — Barcelona, Catalonia, Spain
• Novartis Investigative Site — Barcelona, Catalonia, Spain
• Novartis Investigative Site — Santiago de Compostela, Galicia, Spain
• Novartis Investigative Site — Madrid, Madrid, Spain
• Novartis Investigative Site — Lausanne, CHE, Switzerland
• Novartis Investigative Site — Lausanne, Switzerland, Switzerland
• Novartis Investigative Site — Bern, Switzerland
• Novartis Investigative Site — Bern, Switzerland
• Novartis Investigative Site — Lucerne, Switzerland
• Novartis Investigative Site — Sankt Gallen, Switzerland
• Novartis Investigative Site — Zurich, Switzerland
• Novartis Investigative Site — Birmingham, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.